Suppr超能文献

单链因子XII:活化因子XII的一种新形式。

Single-chain factor XII: a new form of activated factor XII.

作者信息

Ivanov Ivan, Matafonov Anton, Gailani David

机构信息

aDepartment of Pathology, Microbiology and Immunology bDepartment of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA cDepartment of Bioengineering and Organic Chemistry, Tomsk Polytechnic University, Tomsk, Russia.

出版信息

Curr Opin Hematol. 2017 Sep;24(5):411-418. doi: 10.1097/MOH.0000000000000363.

Abstract

PURPOSE OF REVIEW

Exposure of blood to foreign surfaces induces reciprocal conversion of the plasma proteins factor XII (fXII) and plasma prekallikrein (PPK) to the proteases α-fXIIa and α-kallikrein. This process, called contact activation, has a range of effects on host defence mechanisms, including promoting coagulation. The nature of the triggering mechanism for contact activation is debated. One hypothesis predicts that fXII has protease activity, either intrinsically or upon surface-binding, that initiates contact activation. We tested this by assessing the proteolytic activity of a recombinant fXII variant that cannot be converted to α-fXIIa.

RECENT FINDINGS

The proteolytic activity of fXII-T (for 'triple' mutant), a variant with alanine substitutions for arginine at activation cleavage sites (Arg334, Arg344, and Arg353) was tested with known α-fXIIa substrates. FXII-T activates PPK in solution, and the reaction is enhanced by polyphosphate, an inducer of contact activation released from platelets. In the presence of polyphosphate, fXII-T converts fXII to α-fXIIa, and also converts the coagulation protein factor XI to its active form.

SUMMARY

The findings support the hypothesis that contact activation is initiated through activity intrinsic to single-chain fXII, and indicate that preexisting α-fXIIa is not required for induction of contact activation.

摘要

综述目的

血液与异物表面接触会促使血浆蛋白因子 XII(fXII)和血浆前激肽释放酶(PPK)相互转化为蛋白酶α - fXIIa和α - 激肽释放酶。这一过程称为接触激活,对宿主防御机制有一系列影响,包括促进凝血。接触激活的触发机制的本质存在争议。一种假说预测,fXII具有蛋白酶活性,要么是内在的,要么是在与表面结合时,从而启动接触激活。我们通过评估一种不能转化为α - fXIIa的重组fXII变体的蛋白水解活性来对此进行测试。

最新发现

用已知的α - fXIIa底物测试了fXII - T(“三重”突变体)的蛋白水解活性,该变体在激活切割位点(Arg334、Arg344和Arg353)的精氨酸被丙氨酸取代。fXII - T在溶液中激活PPK,血小板释放的接触激活诱导剂多聚磷酸盐可增强该反应。在多聚磷酸盐存在的情况下,fXII - T将fXII转化为α - fXIIa,还将凝血蛋白因子XI转化为其活性形式。

总结

这些发现支持了接触激活是通过单链fXII的内在活性启动的这一假说,并表明诱导接触激活不需要预先存在的α - fXIIa。

相似文献

1
Single-chain factor XII: a new form of activated factor XII.
Curr Opin Hematol. 2017 Sep;24(5):411-418. doi: 10.1097/MOH.0000000000000363.
2
Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation.
Blood. 2017 Mar 16;129(11):1527-1537. doi: 10.1182/blood-2016-10-744110. Epub 2017 Jan 9.
3
Factor XII in coagulation, inflammation and beyond.
Cell Signal. 2018 Nov;51:257-265. doi: 10.1016/j.cellsig.2018.08.006. Epub 2018 Aug 15.
4
A site on factor XII required for productive interactions with polyphosphate.
J Thromb Haemost. 2023 Jun;21(6):1567-1579. doi: 10.1016/j.jtha.2023.02.014. Epub 2023 Mar 1.
5
Factor XII truncation accelerates activation in solution.
J Thromb Haemost. 2019 Jan;17(1):183-194. doi: 10.1111/jth.14325. Epub 2018 Dec 10.
6
Protease activity in single-chain prekallikrein.
Blood. 2020 Feb 20;135(8):558-567. doi: 10.1182/blood.2019002224.
7
Activity of Factor XII-Locarno.
Res Pract Thromb Haemost. 2018 Jan;2(1):168-173. doi: 10.1002/rth2.12054. Epub 2017 Nov 13.
8
Proteolytic activity of contact factor zymogens.
J Thromb Haemost. 2021 Feb;19(2):330-341. doi: 10.1111/jth.15149. Epub 2020 Dec 7.
10
A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.
Blood. 2019 Mar 7;133(10):1152-1163. doi: 10.1182/blood-2018-06-860270. Epub 2018 Dec 27.

引用本文的文献

1
Revisiting the Link Between Factor XII and Recurrent Pregnancy Loss: A Scoping Review.
Am J Reprod Immunol. 2025 Aug;94(2):e70127. doi: 10.1111/aji.70127.
2
Crystal structure of coagulation factor XII N-terminal domains 1-5.
Acta Crystallogr D Struct Biol. 2025 Jul 1;81(Pt 7):380-393. doi: 10.1107/S2059798325005297. Epub 2025 Jun 27.
3
Targeting the Contact Pathway of Coagulation for the Prevention and Management of Medical Device-Associated Thrombosis.
Semin Thromb Hemost. 2024 Oct;50(7):989-997. doi: 10.1055/s-0043-57011. Epub 2023 Apr 12.
4
Model for surface-dependent factor XII activation: the roles of factor XII heavy chain domains.
Blood Adv. 2022 May 24;6(10):3142-3154. doi: 10.1182/bloodadvances.2021005976.
5
A phase I, first-in-human, randomized dose-escalation study of anti-activated factor XII monoclonal antibody garadacimab.
Clin Transl Sci. 2022 Mar;15(3):626-637. doi: 10.1111/cts.13180. Epub 2021 Dec 3.
6
Proteolytic activity of contact factor zymogens.
J Thromb Haemost. 2021 Feb;19(2):330-341. doi: 10.1111/jth.15149. Epub 2020 Dec 7.
8
Protease activity in single-chain prekallikrein.
Blood. 2020 Feb 20;135(8):558-567. doi: 10.1182/blood.2019002224.
9
A non-circulating pool of factor XI associated with glycosaminoglycans in mice.
J Thromb Haemost. 2019 Sep;17(9):1449-1460. doi: 10.1111/jth.14494. Epub 2019 Jun 17.
10
A mechanism for hereditary angioedema with normal C1 inhibitor: an inhibitory regulatory role for the factor XII heavy chain.
Blood. 2019 Mar 7;133(10):1152-1163. doi: 10.1182/blood-2018-06-860270. Epub 2018 Dec 27.

本文引用的文献

1
Factor XII Contact Activation.
Semin Thromb Hemost. 2017 Nov;43(8):814-826. doi: 10.1055/s-0036-1598003. Epub 2017 Mar 27.
2
Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen.
Thromb Haemost. 2017 Apr 3;117(4):671-681. doi: 10.1160/TH16-09-0691. Epub 2017 Jan 26.
3
Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation.
Blood. 2017 Mar 16;129(11):1527-1537. doi: 10.1182/blood-2016-10-744110. Epub 2017 Jan 9.
4
Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors.
Semin Thromb Hemost. 2017 Apr;43(3):270-276. doi: 10.1055/s-0036-1597297. Epub 2017 Jan 4.
5
The Intrinsic Pathway of Coagulation as a Target for Antithrombotic Therapy.
Hematol Oncol Clin North Am. 2016 Oct;30(5):1099-114. doi: 10.1016/j.hoc.2016.05.007.
6
Neutralizing blood-borne polyphosphate in vivo provides safe thromboprotection.
Nat Commun. 2016 Sep 6;7:12616. doi: 10.1038/ncomms12616.
7
HAE Pathophysiology and Underlying Mechanisms.
Clin Rev Allergy Immunol. 2016 Oct;51(2):216-29. doi: 10.1007/s12016-016-8561-8.
8
The role of the tissue factor pathway in haemostasis and beyond.
Curr Opin Hematol. 2016 Sep;23(5):453-61. doi: 10.1097/MOH.0000000000000268.
9
Factor XII: form determines function.
J Thromb Haemost. 2016 Aug;14(8):1498-506. doi: 10.1111/jth.13383. Epub 2016 Aug 2.
10
Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations.
Semin Thromb Hemost. 2017 Apr;43(3):253-260. doi: 10.1055/s-0036-1581128. Epub 2016 Jun 6.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验